ReviewCurrent microbiology2025
Innovative Non-antibiotic Strategies for Combating Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections.
Review in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Potential of phage therapy for the treatment of diabetic foot infections.Folia microbiologica · 2026Review
- Multitarget Mechanisms of (‒)‒Epigallocatechin-3-Gallate Against MRSA: From SraP L-Lectin Targeting to Synergistic Antibiotic Effects.Pathogens (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot infections (DFIs) are a common and serious complication of diabetes mellitus (DM), often caused by methicillin-resistant Staphylococcus aureus (MRSA), which is challenging to treat due to its antibiotic resistance. The ability of MRSA to form biofilms and its resistance to commonly used antibiotics, such as beta-lactams, clindamycin, and trimethoprim-sulfamethoxazole, complicate treatment strategies. The pathophysiology of MRSA in DFIs involves bacterial virulence factors, including adhesion proteins, exotoxins, and immune evasion mechanisms, which allow MRSA to persist in infected wounds despite compromised immune responses in diabetic patients. Diabetes-related conditions such as neuropathy, poor glycemic control, and ischemia further exacerbate the susceptibility to and severity of these infections. With conventional antibiotic therapies facing increasing resistance, alternative non-antibiotic treatment options, including antimicrobial peptides, bacteriophage therapy, and nanotechnology-based interventions, are emerging as promising strategies. This review evaluates these alternative approaches, examining their potential to improve patient outcomes and combat antibiotic-resistant MRSA in DFIs.
Indexed as
Identifiers
40658142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.